Treatment for NSCLC After Progression on Immunotherapy – OncLive
|
Treatment for NSCLC After Progression on Immunotherapy
OncLive Five years ago, to think that we had immunotherapy? And now we’re using it in pretty much all patients, and they’re all benefitting (to some extent). But what we have to remember is that it’s really only about 10% of the patients who have those amazing … |
Science Daily |
Gene therapy halts progression of cerebral adrenoleukodystrophy in clinical trial
Science Daily In a recent clinical trial, a gene therapy to treat cerebral adrenoleukodystrophy (CALD) — a neurodegenerative disease that typically claims young boys’ lives within 10 years of diagnosis — effectively stabilized the disease’s progression in 88 … Bluebird’s gene therapy halts progression of ‘devastating’ disease cALDFierceBiotech NEJM Publishes Interim Data from Study of Gene Therapy in LorenzoRare Disease Report |
|
Synthego And Thermo Fisher To Manufacture, Distribute Synthetic Guide RNA Products For CRISPR
Bio-IT World “Thermo Fisher Scientific prides itself in having a reputation of providing top-quality, reliable products and services to the scientific community,” Helge Bastian, Vice President and General Manager of Synthetic Biology for Thermo Fisher Scientific … |
FierceBiotech |
Bluebird’s gene therapy halts progression of ‘devastating’ disease …
FierceBiotech A single dose of Bluebird Bio’s gene therapy for cerebral adrenoleukodystrophy (cALD) stabilized the disease in 15 of 17 patients over more than two years of … Gene therapy halts progression of cerebral adrenoleukodystrophy in …Science Daily NEJM Publishes Interim Data from Study of Gene Therapy in LorenzoRare Disease Report bluebird bio (BLUE): Interim Results Preview A Significant Catalyst …StreetInsider.com |
WRAL Tech Wire |
Heat Bio’s Pelican subsidiary strikes deal with Selexis to advance cancer immunotherapy
WRAL Tech Wire Durham, N.C. — Pelican Therapeutics, a subsidiary of Durham-based Heat Biologics Inc., has entered a service agreement with Geneva-based Selexis SA to advance development of Pelican’s cancer-fighting therapy candidates. Pelican intends to leverage … |
Crowdfund Insider |
Desktop Genetics Now Live on SyndicateRoom: Utilizing AI in Customizing CRISPR Libraries
Crowdfund Insider Desktop Genetics Ltd (DTG), a software company revolutionising the way biologists use CRISPR genome editing technology, and online investment platform SyndicateRoom have just opened a £1.5 million investment round. DTG plans to use the funds to … |